ArticleNeurology and therapy2022
The Potential Economic Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.
Article in Neurology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Model-Based Economic Evaluations of Interventions for Dementia: An Updated Systematic Review and Quality Assessment.Applied health economics and health policy · 2024Pooled it
- Beyond the Cochrane review: Re-evaluating anti-amyloid therapy in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Study partner profile effects on CDR-SB change in anti-amyloid therapy evaluation.medRxiv : the preprint server for health sciences · 2026Article
- Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Towards a Multi-sectoral Approach to Population Health: A Scoping Review of Cross-sectoral Evaluations of Health Interventions.Applied health economics and health policy · 2026Review
- Evaluating dementia risk prediction in mild cognitive impairment: an early health technology assessment of the AI-Mind tool.GeroScience · 2026Article
- Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer's disease therapy.Frontiers in cell and developmental biology · 2026Review
- Lifetime cost-effectiveness of lecanemab for early Alzheimer's disease.Frontiers in public health · 2026Article
- The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer's Disease in Sweden.PharmacoEconomics · 2025Article
- Economic Evaluation of Lecanemab for Early Symptomatic Alzheimer's Disease in South Korea.PharmacoEconomics - open · 2025Article
- The burden of cognitive impairment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Reducing the burden of informal care through lecanemab: A case of a patient with mild cognitive impairment who continues to drive.Geriatrics & gerontology international · 2025Article
- Lecanemab for mild Alzheimer disease - is there a way forward?Drugs in context · 2025Article
- Evaluating clinical meaningfulness of anti-β-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer's disease.Brain communications · 2024Review
- Lecanemab: Looking Before We Leap.Neurology · 2023Article
- Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?Cost effectiveness and resource allocation : C/E · 2023Article
- Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation.Neurology and therapy · 2023Article
- A Path to Improved Alzheimer's Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer's Disease from the CLARITY AD Trial.Neurology and therapy · 2023Article
- Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.Neurology and therapy · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlzheimer's disease (AD) is a progressive, neurodegenerative disease that affects memory, thinking, and behavior and places a substantial economic burden on caregivers and healthcare systems. This early-phase study aimed to model lecanemab, a humanized monoclonal antibody targeting amyloid protofibrils, for patients with early AD, and estimate the potential value-based price (VBP) of lecanemab + standard of care (SoC) compared to SoC alone given an expected product profile of lecanemab informed by data from a phase II trial from payer and societal perspectives using a broad range of willingness-to-pay (WTP) thresholds in the USA.
methodsA disease simulation model was used to capture how key AD pathology components relate to the clinical and economic presentation of AD. The effects of disease modification and early intervention on disease progression were simulated on the basis of BAN2401-G000-201 trial data as well as published literature. Model outcomes included patient and caregiver quality-adjusted life years (QALYs), total life years, and total care costs including direct medical and non-medical costs for healthcare resource use and indirect costs for caregiving over a lifetime horizon.
resultsLecanemab + SoC was predicted to result in a gain of 0.61 QALYs (societal, 0.64) and a $8707 decrease in total non-treatment costs (societal, $11,214) vs. SoC alone for patients with early AD. For a WTP threshold range of $50,000 to $200,000 per QALY gained, the potential annual VBP of lecanemab was estimated at $9249 (societal, $10,400) to $35,605 (societal, $38,053), respectively. Other patient subsets, treatment stopping rules, and dosing regimens were used to assess the sensitivity of the VBP estimates.
conclusionThe early model predicted that lecanemab would potentially improve long-term health outcomes and reduce formal and informal care costs, resulting in a range of VBPs that reflect the value of lecanemab to society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.